Pink Sheet Podcast: BrainStorm Withdraws NurOwn, NIH Nominee On Drug Pricing, Gene Therapy Long-Term Follow-Up
Pink Sheet reporters and editor discuss BrainStorm’s next steps after withdrawing the NurOwn BLA, NIH director nominee Monica Bertagnolli’s thoughts on drug affordability, and the US FDA’s effort to ensure long-term follow-up of gene therapy patients.
You may also be interested in...
US FDA has received a total of 19 reports of T-cell malignancy involving BCMA- or CD19-directed autologous CAR-T cell immunotherapies and is evaluating the need for regulatory action. Focus on lentiviral and retroviral vectors could extend to safety of other types of gene therapies.
Legislation to delink PBM payments from drug prices advances in House Energy and Commerce health subcommittee, putting a key pharma priority closer to the finish line. Whether patients will see any benefit remains a worry.
Accelerated Approval Drugs’ Fate Rests Heavily On Current Therapeutic Landscape When Confirmatory Trials Are Overdue
At advisory committee meeting on Acrotech's two peripheral T-cell lymphoma drugs, FDA reviewers suggest they are more willing to seek product withdrawal for failure to conduct studies with due diligence when there are numerous available therapies.